- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06313008
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
A Clinical Study Comparing Effects of Empagliflozin Versus Vildagliptin on Inflammatory Biomarkers, and Atrial Function in Coronary Artery Disease Patients With Type 2 Diabetes: EMBA-VILDA-Response Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a prospective, randomized, double-dummy, parallel-group trial that enrolled 120 patients with T2DM. The patients were randomized 1: 1 for 12-week administration of empagliflozin or vildagliptin. by using consecutive ascending randomization numbers in the treatment blocks allocated to each study site. The randomization was stratified by the presence or absence of statin and oral antidiabetic therapy. The randomization list was produced using an automated random number generator.
Clinical parameters, assessment of atrial myocardial function, LVEF%, LA diameter, glycemic and lipid profile, adiponectin, high-sensitivity C-reactive protein, and Sortilin levels will be determined at baseline and after the 6 months of treatment period.
Patient compliance was evaluated by the counting of pills by a physician at selected time-points. In addition, patients were provided with individual diary cards to record administration of the study medication on a daily basis. These cards were checked regularly by site staff.
The study will be approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki and its amendments. All included patients provided written informed consent.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rehab H Werida, Ass. Prof.
- Phone Number: 01005359968
- Email: rehabwrieda@pharm.dmu.edu.eg
Study Contact Backup
- Name: Naglaa Khedr, Prof.
- Email: naglaa_khedr2000@yahoo.com
Study Locations
-
-
Elbehairah
-
Damanhūr, Elbehairah, Egypt, 31527
- Recruiting
- Rehab Hussein Werida
-
Contact:
- Naglaa Khedr, Prof.
- Email: naglaa.khedr@pharm.tanta.edu.eg
-
Contact:
- Lamiaa Khedr, Ass.Prof.
- Email: lamiaa_khedr@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- T2DM patients with chronic stable angina.
- patients with glycated hemoglobin (HbA1c) levels of 6.0-10.0%.
- patients aged 20-80 years.
- patients with a body mass index of ≥ 22 kg/m2.
- patients who provided written informed consent.
Exclusion Criteria:
- patients with type 1 diabetes mellitus or secondary diabetes mellitus.
- patients with renal dysfunction (estimated glomerular filtration rate < 45 mL/min/1.73 m2).
- patients with left ventricular ejection fraction (LVEF) < 30%.
- patients with untreated cancer.
- patients with hepatic cirrhosis.
- patients with liver failure that was virus-, autoimmune- or drug-induced.
- patients with alcoholism.
- pregnant or breastfeeding patients, or those planning to become pregnant during the course of the study.
- patients allergic to empagliflozin or vildagliptin.
- patients with anemia (hemoglobin < 12 g/dL).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empagliflozin
Eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
|
eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
Other Names:
|
Experimental: Vildagliptin
60 patients recieved vildagliptin as add-on group (vildagliptin 50 mg/day as the initial dose).
|
eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LVEF %
Time Frame: 6 months
|
echocardiographic measurements
|
6 months
|
Sortilin (ng/ml)
Time Frame: 6 months
|
Serum Biomarkers
|
6 months
|
LDL (mg/dl)
Time Frame: 6 months
|
Lipid profile
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hsCRP (mg/L)
Time Frame: 6 months
|
Serum Biomarkers
|
6 months
|
HbA1c %
Time Frame: 6 months
|
Glycemic control
|
6 months
|
FBG (mg/dl)
Time Frame: 6 Months
|
Serum level
|
6 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Lamiaa Khedr, Prof., Tanta University
Publications and helpful links
General Publications
- Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8.
- Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J; EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020 Sep 25;19(1):148. doi: 10.1186/s12933-020-01127-z.
- Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19.
- Naing S, Poliyedath A, Khandelwal S, Sigala T. Impact of EMPA-REG OUTCOME(R) on the management of type 2 diabetes mellitus: a review for primary care physicians. Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Sodium-Glucose Transporter 2 Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Empagliflozin
- Vildagliptin
Other Study ID Numbers
- EMBA-VILDA-Response trial.
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Empagliflozin 10 MG
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
Damanhour UniversityRecruitingHeart Failure | Reduced Ejection Fraction Heart FailureEgypt
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Collegium Medicum w BydgoszczyRecruitingMetabolic SyndromePoland
-
Boehringer IngelheimCompleted
-
Yale UniversityBoehringer IngelheimRecruitingEnd Stage Renal Disease on DialysisUnited States
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedSubstance-Related Disorders | Depression | HIV InfectionsUnited States
-
The University of Hong KongResearch Grant CouncilRecruitingCirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 InhibitorsHong Kong